Executive interview – Herantis

Published on 15 April 2019

Herantis Pharma was created by a merger of two Finnish pharmaceutical companies, Hermo Pharma and Laurantis Pharma. Its research is a result of scientific discoveries made by Professor Mart Saarma and Professor Kari Alitalo at the University of Helsinki. Herantis listed on NASDAQ OMX Helsinki First North Finland in 2014.

In this video, CEO Pekka Simula introduces the company and its assets, including its CDNF asset which is under clinical investigation for Parkinson’s disease and utilises the same drug-delivery device highlighted in a recent BBC documentary on GDNF.

Share this with friends and colleagues